Helixgate

Helixgate

Uncategorized

Lilly, Novo dip as proposed Medicare coverage for GLP-1 pilot thrown off balance

Published

on

Two of the biggest insurance providers have expressed reluctance to participate in the government’s BALANCE program that would have made GLP-1 drugs more affordable to patients.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

Nektar’s $325M offering; Maze stock rises; Merck deal rumors; BMS layoffs

Published

on

Nektar Therapeutics prices $325 million public offering: The Bay Area biotech is selling about 3.5 million shares of stock at $92 per share. The proceeds will fund “general corporate purposes,” including …

Continue Reading

Uncategorized

Sanofi’s new CEO faces a reckoning on immunology-focused R&D strategy

Sanofi’s new CEO faces a reckoning on immunology-focused R&D strategy

Published

on

Sanofi CEO Paul Hudson bet big on immunology. When Belén Garijo takes over as CEO next week, she will have to decide whether to continue that wager.

The direction Garijo elects to pursue will likely …​ ​Read More

Continue Reading

Uncategorized

Moderna, after losing US funding, rebounds to start mRNA bird flu vaccine trial

A program that got caught up in HHS’ decision to abandon mRNA research was revived by a public-private coalition and is now beginning a large, late-stage test that could support a future approval.

Read More

Published

on

A program that got caught up in HHS’ decision to abandon mRNA research was revived by a public-private coalition and is now beginning a large, late-stage test that could support a future approval.

Read More

Continue Reading
Advertisement

Trending